Stramsen Biotech is currently preparing for the early phases of clinical trials for its lead drug candidate, SBX1977, a plant-based wound care gel. The initiation of these clinical trials is projected for January 2027.

​

Upon the successful completion of Phase 2 clinical trials for SBX1977, Stramsen Biotech intends to advance additional drug candidates—SBX-1968 for Prostate Cancer, SBX-2021 for Multiple Solid Tumors (cancer), SBX-2022 for Hematological Cancers, and SBX-2000 for cardiovascular diseases—into their respective clinical trial phases.

​

While the comprehensive FDA Investigational New Drug (IND) package for SBX1977 is slated for submission to the FDA within the coming weeks, the company is simultaneously exploring avenues to expedite the approval process for initiating FDA-compliant clinical trials in international territories outside North America.

​

Specifically, Stramsen Biotech is evaluating the feasibility of an accelerated clinical trial pathway for SBX-1977 in select international jurisdictions.  Discussions with potential Contract Research Organization (CRO) partners are ongoing, and further details regarding these clinical trial plans will be disseminated upon the conclusion of negotiations.

​

The rationale underpinning this inquiry is based on the following clinical and logistical considerations:

​

• Pharmacokinetic Divergence: Unlike systemic oral medications, the topical application of SBX1977 is localized, which may mitigate certain systemic toxicity risks typically evaluated in Phase 1 cohorts.

​

• Cohort Incompatibility: Standard Phase 1 protocols involve healthy volunteers. However, the absence of cutaneous lesions in such participants precludes the practical application and efficacy assessment of a wound-healing gel.

​

• Regulatory Precedent: Stramsen Biotech is investigating whether the specific mechanism of action and the localized nature of the delivery system justify a combined Phase 1/2 approach within the targeted jurisdictions.

​

​​

Combining Phase 1 and Phase 2 clinical trials accelerates drug development by evaluating safety and efficacy simultaneously. This approach often lowers total research costs compared to running two completely separate, sequential trials.

​

Key Benefits of Combined Phase 1/2 Trials:

​

• Faster Timelines: Researchers obtain safety and efficacy data concurrently, shortening overall development time. Merging these two phases reduces the time spent waiting between separate trial setups and regulatory reviews, helping potential treatments reach patients sooner.

​​

• Fewer Total Patients: Adaptive or combined designs often require fewer total participants across the combined lifecycle than two distinct, standalone trials. These designs optimize participant numbers by using data from the safety stage directly to inform the efficacy stage, reducing the overall sample size required.

​

• Early Futility Stopping: Combined trials enable researchers to identify ineffective or overly toxic compounds sooner, preventing wasted spending on later development. If a dose proves too toxic or shows no early sign of working, these trials allow researchers to halt the study early, saving resources and protecting participants.

​

• Better Risk-Benefit Decisions: Researchers can evaluate toxicity and patient response simultaneously. This joint data helps identify the optimal recommended dose more reliably than looking at safety alone.

​

• Streamlined Logistics: Utilizing a single protocol and clinical trial platform reduces administrative overhead, contract delays, and startup complexities across study sites.

​

• Cost Savings: Merging the transition-to-proof-of-concept phase eliminates the administrative gap, regulatory refiling overhead, and startup lag of a second discrete trial, frequently saving millions in overall clinical operations and accelerating market entry.